FDA approves Rybrevant Faspro for advanced head and neck cancer

The accelerated clearance rests on a 102-patient trial in which tumours shrank in 42% of participants, the first new option for this group in a decade.

By Ruth Kaplan, Health systems correspondent
. 2-minute read.
Janssen Pharmaceutical building at Leiden Bio Science Park
A Janssen Pharmaceutical Companies building at Leiden Bio Science Park in the Netherlands. Photograph: Bic/Wikimedia Commons (CC BY-SA 4.0)

The FDA granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with advanced head and neck squamous cell carcinoma that returned or spread after platinum-based chemotherapy and immunotherapy, the agency said in a news release. Janssen Biotech holds the approval, which excludes HPV-associated oropharyngeal squamous cell carcinoma. Medical Xpress reported on Wednesday that the FDA cleared the drug for advanced head and neck squamous cell carcinoma.

The agency stated that no new drug for this population had been cleared in the previous ten years.

The decision is based on an open-label, multicenter study of 102 patients, the FDA release said. Tumours shrank or disappeared in 42% of participants, and 56% of responders kept that response for at least six months. The agency said currently approved therapies have response rates of about 20% or lower. CURE identified the study as OrigAMI-4 and reported that 15% of participants showed no detectable cancer on imaging. SurvivorNet added that 28% had a partial response.

Because the approval relied on overall response rate and duration of response as substitute measures, the FDA required confirmatory studies to show clinical benefit. The agency said it is not yet known whether these endpoints will translate into meaningful long-term outcomes. The release explains that accelerated approval permits earlier clearance based on surrogate or intermediate endpoints for serious conditions with unmet need. A randomized trial named OrigAMI-5 must confirm the benefit, SurvivorNet reported; if that study does not verify meaningful clinical benefit, the indication may be withdrawn.

Dr. Zujun Li, a medical oncologist at NYU Langone Health’s Perlmutter Cancer Center who specializes in head and neck cancers, told SurvivorNet that the approval "provides patients with a new treatment option that can achieve meaningful tumor shrinkage, including complete responses in some patients." SurvivorNet noted that the study did not compare Rybrevant Faspro directly with another drug.

The FDA granted the drug Breakthrough Therapy designation for this indication. The single-agent prescribing information warns of hypersensitivity, administration-related reactions, interstitial lung disease or pneumonitis, skin toxicity, eye toxicity, and fetal harm. CURE reported that a rash occurred in 79% of trial participants, making it the most frequent side effect. SurvivorNet listed fatigue, nail changes, mouth sores, and fluid-related swelling as other common side effects.

Rybrevant Faspro is a bispecific antibody that targets EGFR and MET, and it is injected under the skin of the abdomen. Patients receive three weekly doses first, then treatment every three weeks, each injection taking about five minutes, according to SurvivorNet. The trial excluded people who had previously taken an EGFR-targeting drug such as cetuximab, so less is known about that group. For oropharyngeal tumours, a p16 test may help determine whether the cancer is HPV-associated. The approval is the drug’s first outside lung cancer, CURE reported.

Sources: FDA, Medical Xpress, CURE, SurvivorNet

Ruth KaplanHealth systems correspondent

Ruth Kaplan covers hospitals, health systems and the business of care for Clinical Observer. She writes from published reporting, filings and official statements.

Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.